Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000261529 is a long non-coding RNA gene identified as a novel sense transcript within an intronic region of the UBE3A gene. Unlike UBE3A-ATS (the antisense transcript to UBE3A), which has a clear role in imprinting regulation and is implicated in neurodevelopmental disorders like Angelman and Prader-Willi syndromes[3][5], this sense intronic transcript lacks substantial published data regarding its molecular function, disease roles, or utility as a drug target or biomarker[1][3]. Most annotations describe it as an RNA gene of unknown function, not encoding a traditional protein or receptor[1]. It is not listed as interacting with drugs or as having any established mechanism of action in therapeutics.
None known. No mechanisms of drug action are established for this transcript.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, sense intronic to UBE3A (ENSG00000261529).